1. Home
  2. ACOG vs PMVP Comparison

ACOG vs PMVP Comparison

Compare ACOG & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alpha Cognition Inc.

ACOG

Alpha Cognition Inc.

HOLD

Current Price

$9.56

Market Cap

193.6M

Sector

N/A

ML Signal

HOLD

Logo PMV Pharmaceuticals Inc.

PMVP

PMV Pharmaceuticals Inc.

HOLD

Current Price

$1.33

Market Cap

66.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACOG
PMVP
Founded
2000
2013
Country
Canada
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
193.6M
66.1M
IPO Year
2024
2020

Fundamental Metrics

Financial Performance
Metric
ACOG
PMVP
Price
$9.56
$1.33
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$16.00
N/A
AVG Volume (30 Days)
128.3K
321.8K
Earning Date
05-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
41.58
N/A
EPS
N/A
N/A
Revenue
$10,220,275.00
N/A
Revenue This Year
$139.22
N/A
Revenue Next Year
$134.48
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.50
$1.02
52 Week High
$9.99
$1.88

Technical Indicators

Market Signals
Indicator
ACOG
PMVP
Relative Strength Index (RSI) 65.28 60.30
Support Level $5.28 $1.04
Resistance Level N/A $1.49
Average True Range (ATR) 0.76 0.07
MACD 0.00 0.01
Stochastic Oscillator 88.72 95.16

Price Performance

Historical Comparison
ACOG
PMVP

About ACOG Alpha Cognition Inc.

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

About PMVP PMV Pharmaceuticals Inc.

PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.

Share on Social Networks: